Pfizer Inc.
Pfizer Inc. PFE Peers
See (PFE) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PFE | $23.97 | +0.36% | 136.2B | 17.37 | $1.38 | +7.10% |
| LLY | $762.82 | -2.83% | 723B | 62.07 | $12.29 | +0.73% |
| AZN | $69.95 | -1.14% | 433.8B | 28.09 | $2.49 | +2.20% |
| JNJ | $149.71 | -0.68% | 360.2B | 16.65 | $8.99 | +3.37% |
| NVO | $73.79 | -0.30% | 329.6B | 20.38 | $3.62 | +2.18% |
| ABBV | $185.25 | -0.13% | 327.2B | 79.16 | $2.34 | +3.45% |
| NVS | $115.78 | -0.16% | 228.7B | 18.15 | $6.38 | +3.45% |
| MRK | $79.11 | -0.23% | 198.6B | 11.50 | $6.88 | +4.03% |
| AMGN | $289.33 | -0.10% | 155.6B | 26.35 | $10.98 | +3.19% |
| GILD | $108.50 | +0.46% | 135B | 14.02 | $7.74 | +2.86% |
Stock Comparison
PFE vs LLY Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, LLY has a market cap of 723B. Regarding current trading prices, PFE is priced at $23.97, while LLY trades at $762.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas LLY's P/E ratio is 62.07. In terms of profitability, PFE's ROE is +0.09%, compared to LLY's ROE of +0.77%. Regarding short-term risk, PFE is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs AZN Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, AZN has a market cap of 433.8B. Regarding current trading prices, PFE is priced at $23.97, while AZN trades at $69.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas AZN's P/E ratio is 28.09. In terms of profitability, PFE's ROE is +0.09%, compared to AZN's ROE of +0.19%. Regarding short-term risk, PFE is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs JNJ Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, JNJ has a market cap of 360.2B. Regarding current trading prices, PFE is priced at $23.97, while JNJ trades at $149.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas JNJ's P/E ratio is 16.65. In terms of profitability, PFE's ROE is +0.09%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, PFE is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs NVO Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, NVO has a market cap of 329.6B. Regarding current trading prices, PFE is priced at $23.97, while NVO trades at $73.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas NVO's P/E ratio is 20.38. In terms of profitability, PFE's ROE is +0.09%, compared to NVO's ROE of +0.81%. Regarding short-term risk, PFE is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs ABBV Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, ABBV has a market cap of 327.2B. Regarding current trading prices, PFE is priced at $23.97, while ABBV trades at $185.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas ABBV's P/E ratio is 79.16. In terms of profitability, PFE's ROE is +0.09%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, PFE is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs NVS Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, NVS has a market cap of 228.7B. Regarding current trading prices, PFE is priced at $23.97, while NVS trades at $115.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas NVS's P/E ratio is 18.15. In terms of profitability, PFE's ROE is +0.09%, compared to NVS's ROE of +0.31%. Regarding short-term risk, PFE is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for PFE.
PFE vs MRK Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, MRK has a market cap of 198.6B. Regarding current trading prices, PFE is priced at $23.97, while MRK trades at $79.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas MRK's P/E ratio is 11.50. In terms of profitability, PFE's ROE is +0.09%, compared to MRK's ROE of +0.38%. Regarding short-term risk, PFE is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs AMGN Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, AMGN has a market cap of 155.6B. Regarding current trading prices, PFE is priced at $23.97, while AMGN trades at $289.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas AMGN's P/E ratio is 26.35. In terms of profitability, PFE's ROE is +0.09%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, PFE is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs GILD Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, GILD has a market cap of 135B. Regarding current trading prices, PFE is priced at $23.97, while GILD trades at $108.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas GILD's P/E ratio is 14.02. In terms of profitability, PFE's ROE is +0.09%, compared to GILD's ROE of +0.32%. Regarding short-term risk, PFE is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs SNY Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, SNY has a market cap of 116.6B. Regarding current trading prices, PFE is priced at $23.97, while SNY trades at $47.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas SNY's P/E ratio is 16.62. In terms of profitability, PFE's ROE is +0.09%, compared to SNY's ROE of +0.08%. Regarding short-term risk, PFE is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs CELG-RI Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, CELG-RI has a market cap of 113.4B. Regarding current trading prices, PFE is priced at $23.97, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, PFE's ROE is +0.09%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, PFE is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs BMY Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, BMY has a market cap of 95.4B. Regarding current trading prices, PFE is priced at $23.97, while BMY trades at $46.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas BMY's P/E ratio is 17.49. In terms of profitability, PFE's ROE is +0.09%, compared to BMY's ROE of +0.32%. Regarding short-term risk, PFE is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs GSK Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, GSK has a market cap of 77.1B. Regarding current trading prices, PFE is priced at $23.97, while GSK trades at $38.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas GSK's P/E ratio is 18.47. In terms of profitability, PFE's ROE is +0.09%, compared to GSK's ROE of +0.22%. Regarding short-term risk, PFE is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs HZNP Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, PFE is priced at $23.97, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas HZNP's P/E ratio is 61.86. In terms of profitability, PFE's ROE is +0.09%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, PFE is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for PFE.
PFE vs BIIB Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, BIIB has a market cap of 18.6B. Regarding current trading prices, PFE is priced at $23.97, while BIIB trades at $127.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas BIIB's P/E ratio is 12.54. In terms of profitability, PFE's ROE is +0.09%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, PFE is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs GRFS Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, GRFS has a market cap of 7.4B. Regarding current trading prices, PFE is priced at $23.97, while GRFS trades at $8.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas GRFS's P/E ratio is 32.48. In terms of profitability, PFE's ROE is +0.09%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, PFE is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs OGN Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, OGN has a market cap of 2.5B. Regarding current trading prices, PFE is priced at $23.97, while OGN trades at $9.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas OGN's P/E ratio is 3.39. In terms of profitability, PFE's ROE is +0.09%, compared to OGN's ROE of +1.82%. Regarding short-term risk, PFE is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs CTOR Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, CTOR has a market cap of 188.2M. Regarding current trading prices, PFE is priced at $23.97, while CTOR trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas CTOR's P/E ratio is -6.92. In terms of profitability, PFE's ROE is +0.09%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, PFE is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs SCLX Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, SCLX has a market cap of 34.1M. Regarding current trading prices, PFE is priced at $23.97, while SCLX trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas SCLX's P/E ratio is -0.32. In terms of profitability, PFE's ROE is +0.09%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, PFE is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs SCLXW Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, SCLXW has a market cap of 29.5M. Regarding current trading prices, PFE is priced at $23.97, while SCLXW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas SCLXW's P/E ratio is N/A. In terms of profitability, PFE's ROE is +0.09%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, PFE is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs MIRA Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, MIRA has a market cap of 20.6M. Regarding current trading prices, PFE is priced at $23.97, while MIRA trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas MIRA's P/E ratio is -2.60. In terms of profitability, PFE's ROE is +0.09%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, PFE is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs SRXH Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, SRXH has a market cap of 6.8M. Regarding current trading prices, PFE is priced at $23.97, while SRXH trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas SRXH's P/E ratio is N/A. In terms of profitability, PFE's ROE is +0.09%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, PFE is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.
PFE vs CRXT Comparison
PFE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 136.2B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, PFE is priced at $23.97, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 17.37, whereas CRXT's P/E ratio is -0.02. In terms of profitability, PFE's ROE is +0.09%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, PFE is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.